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Skeletal muscle exhibits a remarkable ability to adapt and recover from a variety 
of stressors placed upon it. For example, numerous models of muscle injury, such 
as freeze, crush, and myotoxin, display immediate robust physical damage to the 
tissue when observed histologically. Yet in all three models the damaged tissue is 
able to completely regenerate back to pre-injury levels of fiber numbers and 
function. A complex process of cellular signaling mediates the successful 
regeneration seen in these models, which is ultimately achieved through satellite 
cell proliferation and fusion into new and existing myofibers. However, in more 
severe cases of traumatic injury, such as volumetric muscle loss (VML), there is a 
degree of damage that cannot be overcome endogenously. Instead of muscle 
regeneration, VML results in extensive fibrotic deposition and prolonged 
inflammatory signaling that dramatically reduces muscle function. The persistent 
fibrotic (TGF-β1, CCN2/CTGF) and inflammatory (IL-6, TNF-α) signaling further 
limits the ability of current treatment options to make significant improvements in 
patient outcomes. Moreover, the temporal changes in these processes have not 
been well documented following VML injury. Therefore, a study design using 
terminal time points of 3, 7, 14, 21 and 48 days following VML injury was created 
to evaluate the changes in extracellular proteins leading to fibrosis. Briefly, an initial 
significant increase in the proportion of collagen III was observed, which was 
subsequently reduced and overtaken by collagen I after 48 days post-VML. 
Similarly, histological results indicated an increase in loosely packed collagen 
through 21 days, before switching to an overwhelmingly dense collagen matrix by 
48 days post-VML. Taken together, the window for successful intervention is likely 
before this shift to densely packed collagen I. Future work will evaluate immediate 
and delayed CCN2/CTGF inhibition combined with minced muscle graft 
implantation post-VML injury for effectiveness as interventions. Furthermore, the 
relationship between impaired neuromuscular junctions and fibrotic signaling will 
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Skeletal Muscle Overview 
Skeletal muscle is one of three muscle types in the human body, and makes 
up roughly 40% of total body weight. From a mechanical standpoint, the main 
function of skeletal muscle is force generation, which is transmitted through 
tendons to bones, ultimately causing movement of the appendicular skeleton. 
Skeletal muscle also aids in maintaining posture and breathing. From a metabolic 
standpoint, skeletal muscle acts as a reservoir of amino acids and carbohydrates, 
in addition to producing heat for thermoregulation. The other forms of muscle, 
cardiac and smooth, also generate force but are responsible for various involuntary 
processes such as contraction of the heart and digestion, respectively. Skeletal 
muscle exhibits a large degree of plasticity, or the ability to adapt both positively 
and negatively to different stressors or conditions. This is quite important, as 
skeletal muscle can easily sustain minor acute injuries or become overstressed 
due to the demands of everyday life but is expected to completely return to the 
prior state. 
 
Introduction to Skeletal Muscle Growth and Development 
The development of skeletal muscle, or myogenesis, begins before birth in the 
mesoderm of an embryo. Mesodermal cells take on a skeletal muscle lineage 
through a process called determination, whereby undifferentiated cells are 
programmed to various cell types in the presence of certain molecules and the 
right environment. Myogenic regulatory factors (MRFs) aided by PAX3 and PAX7 
are critical for skeletal muscle development, by prompting the determination of 
undifferentiated mesodermal cells to myoblasts, or skeletal muscle precursor cells. 
Specifically, the MyoD family of transcription factors are thought to be the most 
important factors in the determination and eventual differentiation of myoblasts to 
myotubes, and are expressed exclusively in skeletal muscle. Expression of MyoD 
and Myf5 in somatic cells are an early indication of myogenic determination,1 while 
it has been shown in the absence of these factors cells do not take on a myogenic 
fate and the organism cannot survive after birth.2 
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Following myoblast determination, differentiation is dependent on myogenin 
and MRF4,2 in addition to another family of regulatory factors called myocyte 
enhancer factors (MEFs). The differentiation process involves proliferation of 
myoblasts that fuse together creating a multinucleated cell known as a myotube. 
Myotubes are non-mitotic; they grow and regenerate by the addition of protein and 
nuclei to the existing cell, rather than duplication. Maturation of myotubes to 
myofibers begins with the expression of cytoskeletal proteins, followed by 
myofibrillar proteins such as myosin heavy chain (MyHC). The maturation process 
is completed by the innervation of the fiber via the terminal axon of an α-motor 
neuron. This final step is critical, as without innervation the fiber will die. 
 
Positive Regulation of Skeletal Muscle Growth 
It is believed that the number of muscle fibers at birth is roughly the same 
number of fibers that a person will have throughout their lifespan. Muscle growth, 
or hypertrophy, is the result of adding contractile protein content to the cell, 
whereas muscle loss, or atrophy, results from the degradation of contractile 
proteins. The creation of entirely new skeletal muscle fibers after birth, known as 
hyperplasia, is thought to occur to a very limited extent in humans. Therefore, 
muscle growth results from increasing the size of existing muscle fibers, not the 
addition of new muscle fibers.  Specifically, growth generally involves increase in 
muscle fiber diameter, or cross-sectional area (CSA), rather than length, although 
increase in fiber length can occur to some extent. 
Skeletal muscle growth is achieved by a variety of anabolic processes 
regulated primarily by hormones and endogenous growth factors, which in part 
work to increase protein synthesis. Considered most upstream in this process, 
growth hormone-releasing hormone produced in the hypothalamus stimulates 
growth hormone (GH) secretion by the anterior pituitary gland. Growth hormone 
then increases production of insulin-like growth factor 1 (IGF-1), by binding to 
growth hormone receptors mainly in the liver, but also in skeletal muscle among 
other tissues. Hepatic production of IGF-1 spreads systemically, causing growth 
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stimulating effects throughout the body, however it is thought that local IGF-1 
production is sufficient for skeletal muscle hypertrophy.3 
Although the entire pathway is quite complex, it is accepted that IGF-1 binding 
to its receptor activates phosphatidylinositol-3-kinase (PI3K), leading to the 
phosphorylation of protein kinase B (Akt)4. Subsequently, Akt activation indirectly 
leads to perhaps the most important downstream factor of the pathway, known as 
the mammalian target of rapamycin (mTOR), a serine/threonine kinase.  
Specifically, mTOR is the common subunit of two larger complexes, termed 
mTORC1 and mTORC2, of which mTORC1 is implicated in processes of skeletal 
muscle growth. In a classic signaling cascade, the activation of mTORC1 leads to 
the phosphorylation and activation of S6K1,5,6 in turn increasing protein synthesis 
by the phosphorylation and activation of the ribosomal protein S6 (rpS6). rpS6 is 
part of the small 40S ribosomal subunit and is thought to be involved in translation 
of mRNA to protein. 
Testosterone is another well-known hormone with overall anabolic effects 
leading to skeletal muscle hypertrophy. However, the exact mechanism by which 
it facilitates these results has been somewhat unclear. Testosterone has been 
mainly thought to have genomic effects, increasing DNA transcription of pro-
growth factors after binding to an androgen receptor.7 Hence, these effects are not 
immediate, but rather take hours or days. But similarly to GH and IGF-1, it is now 
believed that mTOR becomes activated downstream of testosterone, producing 
rapid effects.8 Unlike the IGF-1 pathway, it appears Akt is not necessary for 
testosterone mediated mTOR activation. Rather, testosterone can activate the 
MAPK/ERK pathway, which has genomic effects by activating transcription factors, 
but also indirectly activates mTOR.8 A proposed pathway for this is 
phosphorylation of tuberous sclerosis complex 2 (TSC2), a protein that works to 
inhibit mTORC1, by ERK1/2. Phosphorylation by ERK1/2 is inhibitory of TSC2 and 
so it is believed to help activate mTORC1.9 Interestingly, recent studies have 
shown that increases in the amount of circulating testosterone (within the normal 
physiological range) is not indicative of proportional increases in strength or 
muscle growth, but rather the amount of androgen receptors is.10 Therefore, it 
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appears the sensitivity to testosterone is more important for muscle growth than 
the overall amount of the hormone produced. 
A crucial yet complicated step in the process of protein synthesis involves the 
initiation of mRNA translation. There are over a dozen eukaryotic initiation factors, 
all modulating the process in some form.11,12 However, in general the inhibition of 
an initiation factor will impede translation. Thus, another way mTORC1 increases 
protein synthesis is by the phosphorylation of 4E-binding protein 1 (4EBP1), 
causing it to dissociate from the translation initiation factor 4E (eIF-4E).5,6 When 
4EBP1 is bound to eIF-4E, translation of mRNA is repressed, and therefore 
dissociation of 4EBP1 can increase translation and protein synthesis. In a similar 
manner, insulin is important for protein synthesis by inhibition of glycogen synthase 
kinase 3 (GSK3) through activation of the PI3K/Akt pathway. Although GSK3 was 
named for its role in limiting glycogen synthesis, it is now known to have numerous 
effects. Phosphorylation of initiation factor 2B (eIF-2B) by GSK3 suppresses its 
activity,9 however Akt prevents this by phosphorylating GSK3. 
Insulin and IGF-1 also appear to suppress protein breakdown by inhibiting the 
ubiquitin ligases atrogin-1 and MuRF1 through the same PI3K/Akt pathway.13 Akt 
phosphorylates FoxO, inactivating the transcription of atrogin-1 and MuRF1.4 
Simply put, these molecules work by labeling targeted proteins with ubiquitin for 
subsequent proteasomal degradation. Therefore, the effect of insulin and IGF-1 in 
skeletal muscle is two-fold, they stimulate the rate of protein synthesis while 
simultaneously slowing the rate of protein degradation, effectively increasing 
muscle growth. At all times throughout the lifespan there is protein turnover 
consisting of concurrent synthesis and degradation. The net balance of these two 
processes plays a large role in determining whether skeletal muscle is achieving 
hypertrophy, atrophy, or maintaining size. Such that a higher rate of protein 







Negative Regulation of Skeletal Muscle Growth 
Skeletal muscle growth is negatively regulated by members of the transforming 
growth factor beta (TGF-β) family, namely myostatin. The mechanisms by which 
myostatin exerts its negative influence on muscle growth are thought to be 
numerous. In relation to protein synthesis pathways, myostatin may inhibit Akt,4,14 
which concurrently limits mTORC1 activation and increases FoxO activation. In 
opposition to insulin and IGF-1, this would decrease protein synthesis and increase 
degradation by increasing atrogin-1 and MuRF1 expression. Myostatin most likely 
exerts these effects by phosphorylation of Smad2 and 3 transcription factors 
through binding to activin type IIB receptors.4,15,16 
Research on this topic has been helped in part by rare yet naturally occurring 
deletions of the myostatin gene in numerous mammals, including humans.17,18,19 
In all cases, skeletal muscle mass was significantly increased compared to 
typically developing members of the given species. Notably, McPherron et al. 
showed that in myostatin knockout models of mice, the increased muscle mass 
was due to a combination of hyperplasia and hypertrophy.20 This has led to the 
belief that myostatin regulates skeletal muscle growth by two separate 
mechanisms. Indeed, manipulation of myostatin expression in different transgenic 
models leads to differential muscle growth in terms of hypertrophy and 
hyperplasia.21,22 In agreement with Lee,16 it would appear myostatin has distinct 
roles in regulating prenatal muscle fiber myogenesis and postnatal muscle fiber 
growth. The resulting increase in hyperplasia or hypertrophy would be entirely 
dependent on the timing of myostatin inhibition. Reduced myostatin expression 
during embryotic development would result in increased fiber number, but not 
necessarily size; while reduced myostatin expression after birth would result in 
increased fiber size, but not necessarily increased fiber numbers. 
Recent work has also implicated the increase in muscle mass from myostatin 
knockout models is accompanied by a decrease in the relative proportion of 
extracellular matrix (ECM) proteins surrounding muscle fibers.23 Likewise, Li et al. 
found that myostatin increases proliferation of muscle fibroblasts in vitro and vivo.24 
The dual role of myostatin as an inhibitor of muscle growth and stimulator of ECM 
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growth makes it an intriguing therapeutic target. However, it appears the regulation 
of muscle growth by myostatin is highly conserved and serves an overall beneficial 
purpose.16 Knockout models of myostatin in mice have shown the typical increase 
in muscle mass, yet somewhat differ in results regarding maximal force 
production.25,26 Amthor et al. found no increase in overall maximal force between 
wild-type and myostatin knockout mice,25 while Mendias et al. found an increase 
in maximal force following myostatin knockout.26 Yet, when adjusted for the size of 
the muscle (i.e., specific force), both studies found a reduced force output in the 
myostatin knockout groups, suggesting myostatin plays a role in maintaining the 
efficiency of force production. This is potentially due to the weakening of tendons 
with myostatin inhibition, as suggested by Mendias et al.27 Compared to wild-type 
controls, tendons from myostatin knockout mice obtained a higher peak stress, but 
less than half of the peak strain before yielding, indicating a more brittle tendon. 
Interestingly, they also exhibited a higher stiffness compared to wild-type, even 
though overall collagen content was reduced.27 Thus, the probability of injury is 
likely increased with larger muscle mass and weaker tendons. In addition, 
oxidative capacity is reduced in genetic loss of myostatin, most likely due to a 
reduction in overall mitochondria content.25 Therefore, myostatin is most likely a 
healthy regulator of muscle mass in the typical population, but its inhibition could 
still be a useful target in certain populations characterized by muscle atrophy and 
increased fibrosis. 
 
External Factors Regulating Skeletal Muscle Growth 
External factors contributing to muscle growth include nutrition, exercise, and 
the overall whole body energy state. A fasted or starved state (i.e., low-energy) 
promotes overall catabolism, as the body needs to break down macronutrients for 
energy to maintain homeostasis. Conversely, a fed state (i.e., high-energy) 
promotes the storage or build-up of macronutrients and therefore has an overall 
anabolic effect.28 The influence of energy states on muscle growth is largely due 
to AMP-activated kinase (AMPK).29 When energy levels are low, there is an 
increase in the amount of ADP and AMP relative to ATP, causing activation of 
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AMPK.30 The end result of AMPK activation in this case is the increased production 
of ATP. But not only will activation of AMPK increase ATP production; it will 
simultaneously limit ATP usage for anabolic processes such as the synthesis of 
glycogen and protein, and thus muscle growth.30 Specifically, AMPK inhibits 
protein synthesis by the direct phosphorylation of the mTORC1 subunit, Raptor.31 
Although oversimplified here, the ability of AMPK to sense the body’s energy state 
can be thought of like a building’s thermostat. When a building becomes too cold, 
the thermostat senses the drop in temperature and signals the furnace or heating 
system to produce warm air; just as when the level of ATP drops in the body, AMPK 
senses the rise in AMP and signals the breakdown of glycogen, lipids, and 
potentially proteins to produce more ATP. 
Fatty acid oxidation, or β-oxidation, is the preferred energy system in skeletal 
muscle at rest, along with aerobic glycolysis. Protein is also capable of contributing 
to energy production; however, this is not ideal as it can result in muscle atrophy if 
utilized in a prolonged state. Additionally, when proteins are broken down to amino 
acids for fuel use, the amino group needs to be removed. In what is known as the 
glucose-alanine cycle, branched chain amino acids from muscle protein are 
converted to glutamate and ketoacids. Alanine transaminase then converts 
glutamate and pyruvate to alanine, which is shuttled to the liver (along with 
ketoacids) to produce glucose via the gluconeogenic pathway. The glucose made 
in the liver can then be shuttled back to the muscle for ATP production.32 
Importantly, once alanine or other amino acids reach the liver, the amino group 
can be removed in the form of urea and excreted. The use of protein as a fuel 
source is typically only necessary in times of stress, such as during intense 
exercise or an extended fasting period. 
Exercise is a well-known modulator of muscle growth and metabolism, however 
it is an intricate process. Differing intensities and durations of exercise will play a 
large role on the outcome of overall anabolism or catabolism. Resistance exercise, 
or weight training, is a well-known stimulator of skeletal muscle hypertrophy and 
strength. Although an acute bout of high intensity weight training will increase 
muscle protein breakdown, it also increases protein synthesis post-exercise for up 
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to 48 hours.33,34 However, without food intake before or after a training session, 
the overall protein balance will most likely remain negative,33,34 highlighting the 
importance of nutrition to stimulate positive protein accretion and muscle 
hypertrophy. Interestingly, numerous studies have found that exercise regimens 
containing resistance training concurrently with endurance training exhibit 
dampened hypertrophy and strength gains compared to resistance training 
alone.35,36,37  This could be because lower intensity, long duration exercise mimics 
the low-energy status produced by fasting, as ATP stores are gradually used up to 
produce continued muscle contraction and movement. Large volumes of 
endurance exercise generally result in a net protein loss if not accompanied by 
adequate nutrition,38 due to an increase in protein breakdown for fuel use.39 
Although the degree of activation is dependent on exercise intensity, AMPK is 
thought to mediate this process.40,41 Therefore, endurance exercise in a fasted 
state can be considered overall catabolic, hindering muscle hypertrophy and 
strength. However, it is difficult to make broad claims on this subject because of 
the numerous variables alluded to previously, including intensity, duration, 
frequency, training status and nutrition. Minor adjustments in any of these variables 
can produce differing results, as seen by the amount of conflicting studies on the 
subject.36,42,43,44 Recently, Kazior et al. found that endurance exercise actually 
augments the effects of resistance training on skeletal muscle hypertrophy and 
mTOR activation.43 Clearly, endurance exercise can elicit increases in skeletal 
muscle force output and hypertrophy to an extent, but is most likely dependent on 
concurrent increases in calories consumed, as is resistance training. 
It is widely agreed upon that endurance training results in an increased 
oxidative capacity of skeletal muscle. The major mechanism responsible for this 
adaptation is the increase in mitochondrial content,45 allowing greater fat oxidation 
and a more sustained utilization of glycogen.46 Mitochondrial biogenesis is heavily 
regulated by the transcriptional factor peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α). The upregulation of PGC-1α is achieved 
through a variety of pathways. The promoter region of PGC-1α contains binding 
sites for cAMP response element binding protein (CREB) and MEF2.47 Exercise 
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induced increases in Ca2+ causes activation of calmodulin kinase (CaMK), which 
phosphorylates CREB, promoting transcription of PGC-1α.48 Likewise, AMPK 
activation due to endurance exercise can increase CREB phosphorylation. 
Concurrent increases in hydrogen peroxide (H2O2) from endurance exercise 
activate p38 MAPK, which can phosphorylate MEF2 and thus also increase PGC-
1α transcription.49 Once translated, PGC-1α increases the replication of 
mitochondrial DNA through activation of mitochondrial transcription factor A 
(TFAM). 
Altogether, skeletal muscle has a remarkable ability to adapt to different 
stressors placed upon it. In fact, such stressors are necessary to maintain and/or 
improve overall health of the muscle tissue. Certain molecular products that are 
typically considered harmful to tissue, such as H2O2, can elicit beneficial changes 
to skeletal muscle in a hormetic effect. Without these signals, muscle protein will 
be broken down for other uses and mitochondrial turnover will become stagnant, 
leading to muscle atrophy and reduced function. 
 
Skeletal Muscle Repair and Regeneration 
The repair and regeneration of existing muscle fibers follows a similar process 
as that of newly developing fibers outlined previously. Because myofiber nuclei are 
post-mitotic and therefore unable to re-enter a proliferative state, the activation of 
skeletal muscle stem cells, known as satellite cells, is crucial to the regeneration 
process. Satellite cells remain in a quiescent state beneath the basal lamina until 
activated upon stress and damage to the muscle.50 An inflammatory response is 
triggered in response to this stress, which involves the influx of phagocytes and 
cytokines (IL-6, TNF).51 These both work to clear necrotic debris from the site of 
injury. Activated satellite cells then proliferate at the inner basal lamina and fuse 
into multinucleated myotubes. These myotubes finally fuse with the existing 
myofibers and become innervated to complete the regeneration process, similar 
to that of newly developing muscle fibers. 
An important biomarker of quiescent satellite cells in adult skeletal muscle 
tissue is the transcription factor paired box protein 7 (Pax7).52 Activated satellite 
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cells increase in size and maintain Pax7 expression along with myogenic 
regulatory factors, which can include Myf5 and/or MyoD. Determination of 
activated satellite cells into myoblasts are then characterized by a loss of Pax7 
expression and an increase in MRF expression including Myf5, MRF4, and MyoD. 
Finally, differentiation of myoblasts into myotubes and myofibers is highlighted by 
the presence of myogenin and MyHC in the continued presence of MRFs. 
Importantly, quiescent satellite cells (Pax7+/Myf5-) are able to self-renew, thereby 
repopulating the stem cell niche for continued regeneration. 
There have been debates regarding the necessity of Pax7+ satellite cells for 
skeletal muscle regeneration, as it appears other progenitor cells are capable of 
contributing to the process. Ferrari et al. first demonstrated that bone marrow-
derived progenitors are able to migrate into skeletal muscle and assist in 
regeneration.53 This was followed by studies showing numerous other cells can 
take on a myogenic lineage, including mesoangioblasts and pericytes.54,55 
However, in 2011 Lepper et al. determined that although other progenitors can 
assist with skeletal muscle regeneration, Pax7+ satellite cells are a necessity, as 
complete elimination of them inhibits regeneration.56 
 
Skeletal Muscle Contraction 
Skeletal muscle contraction can be broken down broadly into two main phases, 
excitation-contraction (E-C) coupling and cross-bridge cycling. The process of E-
C coupling begins with an action potential, or nerve impulse, sent from an α-motor 
neuron in the central nervous system to the muscle via descending axons. The 
impulse is propagated down the axon by a change in polarity caused by gated ion 
channels allowing Na+ into the axon and K+ out of the axon, until it reaches the 
neuromuscular junction (NMJ). The speed at which this impulse travels to the 
muscle is increased by the presence of myelin sheaths, which act as insulators to 
the nerve fiber. One motor neuron is responsible for innervating multiple muscle 
fibers, known as a motor unit. Smaller motor neurons are typically associated with 
smaller muscle fibers, known as slow-twitch, which are relatively fatigue resistant. 
Conversely, large motor neurons are associated with larger muscle fibers, or fast-
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twitch, which produce more force but fatigue more quickly. According to the all-or-
none principle,57 when an action potential is initiated by a motor neuron, all of the 
fibers within its motor unit will contract together at its greatest strength, or if the 
stimulus is too weak it will not contract at all. There is no ability for a muscle 
contraction to occur at a degree less than maximal for that given motor unit. 
However, according to the size principle,58 smaller motor units will always be the 
first to activate during a given task, and if more force is needed, larger motor units 
will be recruited in an orderly fashion. Because of this, one is able to control the 
amount of force output needed for a given task and not waste energy using large 
motor units for tasks that only require a small amount of force. 
Once an action potential reaches the NMJ, it releases a neurotransmitter, 
acetylcholine, which binds to receptors on the sarcolemma.59 The binding then 
activates an electrochemical gradient across the muscle membrane, similar to how 
the action potential was originally sent from the central nervous system. This can 
be thought of like a rock being tossed into a pond. The rock hits the water and the 
water ripples out in all directions from that point. However, the further from the 
point of contact, the weaker the ripples become. In terms of electrophysiology, this 
phenomenon is known as the length constant, which describes how the potential 
diminishes from a given point of event. The NMJ is akin to this point, whereby the 
signal begins and can spread across the muscle. But, unlike the ripples of water 
which diminish as they spread, ion channels located along the transverse tubule 
(T-tubule) network allow the potential to be propagated and maintain equal 
strength throughout the entirety of the muscle. This is extremely important as it 
allows muscles to produce a much larger force than they could without T-tubules 
maintaining the action potential.60  
Located along the T-tubules are voltage-gated channels known as 
dihydropyridine receptors (DHPR), which are physically coupled to ryanodine 
receptors (RyR) on the sarcoplasmic reticulum (SR).61 Depolarization of the T-
tubule membrane caused by an action potential triggers the DHPR to activate the 
RyR, which allows calcium (Ca2+) to be released from the SR. This process is the 
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final step in E-C coupling, as the release of Ca2+ ultimately triggers a muscle 
contraction. 
As previously noted, the “second phase” in skeletal muscle contraction is 
known as cross-bridge cycling, and/or the sliding filament theory. Structurally, 
individual muscle fibers are divided into sections called sarcomeres.62 Sarcomeres 
contain the two main contractile proteins contributing to the sliding filament theory, 
actin and myosin. On a simplistic level, muscle contraction is achieved by myosin 
pulling on actin, which shortens the length of each sarcomere and thus the muscle 
as a whole. The actin filament is anchored to the Z-disk and has some degree of 
overlap with myosin on both ends (Figure 1). As the myosin heads bind to actin 
on both ends, it pulls actin towards each other and causes the sarcomere, the 
length between two Z-disks, to shorten. A cross-bridge refers to a single myosin 
head bound to globular actin. During a muscle contraction, there is a constant cycle 
of myosin binding, pulling, and releasing from actin, hence the term cross-bridge 
cycling. A good analogy here is that of a rowing team, with the oars corresponding 
to myosin and the water actin. However, in skeletal muscle the individual myosin 
heads do not cycle in unison, but rather in an asynchronous fashion so that at any 
given time during a contraction there are both bound and unbound cross-bridges. 
This allows for fluid motion on a macro level. Perhaps rowing crews could be more 
efficient by alternating their strokes, in which case there would be a reduction in 
the amount of velocity fluctuation between each row. 
Cross-bridge cycling is much more complicated upon closer examination.  
Myosin heads can only bind to actin at certain locations, which happen to be 
blocked during rest by the protein tropomyosin. In order for a cross-bridge to form, 
this binding site needs to be exposed to myosin. A protein called troponin, attached 
to tropomyosin, is responsible for making this happen. Troponin is a complex made 
 
Figure 1. Structure of a sarcomere. Myosin (thick filament), actin (thin filament), Z-
disk (anchoring thin filaments). 
Figure was produced using Servier Medical Art (https://smart.servier.com) 
14 
 
up of three proteins, troponin-T (TnT), troponin-C (TnC), and troponin-I (TnI). As 
mentioned previously, the final step in E-C coupling involves the release of Ca2+ 
into the sarcoplasm. Ca2+ then binds to TnC, causing a conformational change in 
the troponin-tropomyosin complex and exposing the actin binding site to myosin. 
Once the myosin head is bound to actin, it can then undergo a powerstroke, 
effectively shortening the sarcomere before detaching and repeating the process. 
The biochemical side of the cross-bridge cycle is controlled by ATP, as it is 
needed for the release of myosin from actin after the powerstroke. Without ATP, 
muscles would remain in a rigor state which is seen acutely after death, as the 
body stops producing ATP and the myosin heads become stuck in a post-
powerstroke state bound to actin. In healthy muscle however, ATP binds to 
myosin, causing it to dissociate from actin. Myosin then hydrolyzes the ATP, 
making it an ATPase itself, something not discovered until 1939 by Engelhardt and 
Ljubimowa.63 The hydrolysis re-primes myosin to a pre-powerstroke state, ready 
to bind to actin once again, assuming Ca2+ is still present to expose the binding 
site. The products of hydrolysis, ADP and Pi, are released while myosin is bound 
to actin. First, the release of Pi from myosin results in the powerstroke and a more 
strongly bound state. ADP is then released post-powerstroke to allow for ATP to 
rebind and release the cross bridge. The cycle continues until Ca2+ is pumped back 
into the SR, which allows the muscle to relax. Thus, diminished Ca2+ release from 
the SR during intense exercise is generally thought to be a main contributor to 
muscle fatigue and decreased force output.  
 
Length/Tension Relationship 
As previously noted in Figure 1, actin is anchored to the Z-disk and overlaps 
with myosin. It is well understood that the amount of overlap is crucial to the 
potential force of muscle contraction, which is generally referred to as sarcomere 
length. The longer the sarcomere, the less overlap between actin and myosin, and 
therefore less myosin heads can be in contact with actin at the initiation of muscle 
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contraction. On the other hand, too much overlap means more myosin heads can 
be in contact with actin, however there is less space to contract before actin 
filaments interfere with each other. The optimal sarcomere length is somewhere in 
the middle, allowing maximal cross-
bridges to be formed and enough room for 
forceful contraction without interference. 
The relationship between sarcomere 
length and tension can be shown by 
isometrically contracting muscle at 
various lengths. An isometric contraction 
is one that does not result in a change in 
length, but rather produces tension in a 
static position, often opposing some type 
of force, such as gravity. This differs from 
concentric contraction, which produces 
tension while shortening the muscle, and eccentric contraction, which produces 
tension while the muscle is lengthening. Examples of these include the biceps 
brachii during a dumbbell curl, and the quadriceps muscle group during the landing 
phase of a jump, respectively. The greatest tension an actively contracting muscle 
can achieve is when that muscle is at optimal length Figure 2. If the muscle is 
shortened or lengthened before actively contracting, the tension produced is 
drastically reduced. However, if the muscle is stretched past its optimal length, 
there is a strong resistance to that stretch which will produce tension, known as 
passive tension. Whereas active tension is due to the cycling of cross bridges and 
controlled biochemically, passive tension is caused by resistance of opposing force 
mainly due to the large protein titin. Titin is anchored to the Z-disk on one end, and 
the M-line, the center of the sarcomere, on the other end. Titin physically produces 
tension by having elastic properties, similar to a rubber band. At rest the protein 
has folded domains which unfold as the muscle stretches, providing tension. By 
equating titin to a spring under Hooke’s Law, the amount it stretches is directly 
proportional to the force with which it pulls. Because of this, the total amount of 
 
Figure 2. Hypothetical graph of 
length/tension relationship. Total tension 
(solid line) combines active and passive 
(dashed lines) increments when muscle is 
stretched beyond resting length.  
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tension a muscle can produce is increased by combining active and passive 
tension (solid line in Figure 2). As an easy example, one can lower a much heavier 
amount of weight to the ground than can be picked up off the ground. This is 
because while lowering weight controllably, the primary muscles are lengthening, 
and therefore force is being produced both actively and passively. When picking 
weight up off the ground, only active tension is produced, i.e., titin does not 
contribute to the force production. 
 
Force/Velocity Relationship 
Another important concept of skeletal 
muscle function to understand is the force-
velocity curve, which has a somewhat 
inversely proportional relationship. That is, as 
the velocity of a concentrically contracting 
muscle increases, the force of contraction 
decreases, and vice-versa. If one were to map 
power on the same graph, which for a 
constant force and velocity equals force times 
velocity, it should have a relatively parabolic 
shape. Optimal power is achieved around roughly one-third of peak velocity, and 
moves towards zero as one approaches either maximal force or maximal velocity. 
In reality, the force-velocity relationship slightly differs for everybody and can be 
modulated by training, as shown in Figure 3. For example, the shape of the curve 
for an Olympic weightlifter versus an Olympic sprinter will likely be different. The 
weightlifter should exhibit more power near maximal force, while the sprinter 
should achieve greater power near maximal velocity. 
 
Non-Contractile Aspects of Skeletal Muscle 
In addition to the contractile proteins comprising skeletal muscle, there are also 
very important non-contractile proteins within and surrounding muscle fibers. 
Muscle tissue can generally be divided into layers based on connective tissue, 





subjectively. Single muscle 
fibers are surrounded by 
endomysium, bundles of 
muscle fibers (fascicles) 
are surrounded by 
perimysium, and the whole 
muscle unit is surrounded 
by epimysium (Figure 4).64 
These layers of connective tissue are known as the extracellular matrix, or ECM. 
The ECM is predominately comprised of varying collagen isoforms, which 
physically provide a level of elasticity to the muscle and allows force transmission 
from muscle to bone to produce movement. Perhaps even more so than titin 
(described above), collagen is heavily implicated in the amount of passive tension 
produced by muscle fibers. There are currently 28 known types or isoforms of 
collagen, which is the most abundant protein found in all mammals.65 Type I 
collagen is the most abundant isoform in skeletal muscle ECM. The perimysium 
layer and tendons are almost entirely collagen I, while the endomysium and 
epimysium layers are typically equal parts collagen I and III.66 Type IV collagen, 
along with some type VI, makes up the muscle basement membrane. In this way, 
type IV collagen connects skeletal muscle fibers to the ECM, as the glycoprotein 
laminin binds to the collagen IV network and is also anchored to the dystrophin-
glycoprotein complex spanning the sarcolemma. Dystrophin, along with many 
other structural proteins such as desmin, make up costameres physically coupling 
the sarcomere to the sarcolemma. Thus, the path of force transmission generated 
by actin and myosin moves through costameric proteins to the muscle membrane, 
to laminin and collagen IV, to endomysium and perimysium collagens I and III, to 
tendons, and finally bones. The entire process is not fully understood but generally 
accepted that force is transmitted close to this fashion. It is easy to see then, that 
the ECM plays quite an important role in optimal functioning of skeletal muscle. 
 
Figure 4. Skeletal muscle organization. 
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Collagen is unique from other proteins in that it is made up of roughly 12.5% 
hydroxyproline. Because of this relatively high content compared to other proteins, 
hydroxyproline is commonly used as a biochemical marker for total collagen 
content. A single collagen molecule has a triple-helix structure made up of three 
polypeptide chains and is also referred to as a tropocollagen. Tropocollagens link 
together to form a collagen fibril, and collagen fibrils link together to form a collagen 
fiber, which can also link to form cables. These cross-links are formed by covalent 
binding of pyridinoline to lysyl and hydroxylysyl residues on the collagen 
molecules, catalyzed by the enzyme lysyl oxidase (Lox). Covalent cross-linking 
within varying levels of collagen fibrils and fibers is thought to contribute to the 
amount of stiffness observed in a given tissue. More cross-linking presumably 
leads to a more rigid fiber. It is generally believed that cross-linking increases as 
collagen matures, and therefore newly synthesized collagen will have less cross-
linking. Additionally, cross-linking may play a role in the solubility of collagen, as 
fibers with more cross-links are harder or even impossible for collagenases, such 
as matrix metalloproteinases (MMPs), to degrade. However, much of this is still 
speculation as studies have shown mixed results. 
Many aspects of the ECM are not as well understood as the muscle fibers they 
surround. Historically, skeletal muscle ECM has been thought of as a static 
environment giving support to muscle fibers, however recently it is beginning to be 
understood as an extremely important dynamic aspect of healthy muscle. For 
example, proteoglycans within ECM provide storage for growth factors and thus 
play a large role in cell signaling and remodeling. As the name suggests, 
proteoglycans consist of a core protein bound to a glycosaminoglycan (GAG) 
chain. The core protein typically binds to collagen at specific locations on the fibril. 
Considerable research has been done on the role of decorin and biglycan, which 
belong to the small leucine-rich repeat (SLRP) group of proteoglycans. Because 
of their hydrophilic nature, the most well-known function of these molecules is to 
provide hydration to the ECM, supporting the elastic properties of collagen. 
However, along with this general physical support by binding to collagen, decorin 
is thought to regulate collagen fibrillogenesis, preventing abnormal collagen fiber 
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formation. Genetic knock-out models of decorin and biglycan have resulted in 
increased collagen fiber diameter, as well as reduced circularity of collagen fibers 
in tendons.67,68 Adding to its importance for a healthy ECM, decorin has been 
shown to bind with TGF-β family members, reducing the effects of myostatin and 
TGF-β1,69,70 both pro-fibrotic proteins. 
 
ECM Turnover – Synthesis & Degradation 
The synthesis of ECM components is produced chiefly by fibroblasts. 
Fibroblasts reside within the ECM, which undergoes a continual remodeling from 
deposition of components by fibroblasts and degradation by enzymes such as 
MMPs. In a healthy regeneration model, damaged muscle fibers activate an 
immune response that recruits mast cells and various white blood cells to the area, 
such as neutrophils, monocytes, lymphocytes and eosinophils. Mast cells release 
histamine along with numerous cytokines, ultimately leading to the transition of 
monocytes to M1 macrophages. M1 macrophages are generally considered pro-
inflammatory, secreting nitric oxide, tumor necrosis factor (TNF), and various 
interleukins, in addition to promoting proliferation of satellite cells.71 Although these 
factors are important in the immediate response to a stressor, M1 macrophages 
will quickly transition to anti-inflammatory M2 macrophages. M2 macrophages play 
a large role in the remodeling phase, secreting TGFβ1, IGF1, fibronectin, and 
activating fibroblasts to secrete collagen. M2 macrophages can also promote the 
differentiation and fusion of satellite cells.71 
Formation of collagen fibers by fibroblasts begins with the transcription and 
translation of alpha peptides, which undergo multiple post-translational 
modifications inside the cell. The alpha peptides form a polypeptide chain, 
predominately made of the amino acids glycine and proline. An important step is 
the hydroxylation of proline and lysine residues on the alpha chains, which uses 
Vitamin C as a cofactor, forming hydroxyproline and hydroxylysine.72 
Subsequently, three alpha chains will form a triple helical structure in the 
endoplasmic reticulum, known as a procollagen. Different collagen types will have 
different makeups of alpha chains within its triple helix. For example, type I 
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collagen is made up of two α-1 chains, and one α-2 chain. Procollagen is then 
secreted outside of the fibroblast cell, where it becomes tropocollagen by the 
removal of its pro-peptide ends. As previously described, tropocollagen molecules 
form collagen fibers by covalent crosslinking. 
In healthy tissue, the rate of collagen synthesis is matched by the rate of 
collagen degradation to maintain a proper microenvironment for muscle fibers. 
Degradation begins with the cleavage of collagen fibers by proteases known as 
MMPs. The exact process of collagen degradation continues to be studied and is 
quite fascinating. Because collagen molecules are so large, they cannot be 
cleaved whole, but need single alpha chains to be exposed for proteolysis. 
Importantly, MMPs contain both a hemopexin domain and a catalytic domain. The 
hemopexin domain binds and unwinds the collagen triple helical structure, allowing 
the catalytic domain to hydrolyze the separated collagen alpha chains. In addition 
to collagens, MMPs also degrade other ECM structures such as proteoglycans. 
Interestingly, the proteolysis of decorin by MMP-2, -3, or  -7 can result in the 
release of TGF-β1, and therefore increase overall ECM accumulation.73  
Tissue inhibitors of metalloproteinases (TIMPs) work to inhibit the actions of 
MMPs, further adding to the complexity of ECM turnover. Specific members of the 
TIMP family vary in their ability to inhibit specific members of the MMP family. 
Furthermore, the overall effect of TIMPs on ECM turnover is not straightforward, 
but is likely dependent on the type of tissue and health of that tissue.74 For 
example, Kitamura et al. observed that under high glucose conditions, TIMP 
expression was increased and MMP expression suppressed in cultured glomerular 
mesangial cells,75 suggesting hyperglycemia in diabetic patients contributes to 
renal pathology by an inhibition of ECM degradation. McLennan et al. further 
observed that connective tissue growth factor (CCN2 or CTGF), a known pro-
fibrotic factor, mediates the inhibition of ECM degradation caused by 
hyperglycemia.76 In these cases, increased TIMP-1 expression is associated with 
ECM accumulation due to the inhibition of proteolysis, which is commonly seen in 
various fibrotic tissues.77,78,79  However, studies have also shown that genetic 
TIMP-1 deficiency in mice does not lead to a reduction of ECM accumulation 
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caused by several pathologic tissue models compared to wild-type mice, and can 
even worsen the condition.80,81 In skeletal muscle, both MMPs and TIMPs are 
upregulated during wound healing. MMPs are thought to aid in the migration of 
satellite cells across the basement membrane by removing collagen 
obstructions.82 There is some evidence that TIMPs help to control inflammation, 
which is likely why their complete removal is detrimental to wound healing.81 Yet, 
as with other tissues, the ratio of TIMPs relative to MMPs in skeletal muscle 
pathologies is typically increased. Accordingly, there is some evidence that 
injection of MMP-1 into fibrotic skeletal muscle reduces overall collagen content.83 
 
Fibrosis 
In pathologic conditions of skeletal muscle, the formation of collagen and other 
ECM components accumulate excessively, resulting in fibrosis. Chronically fibrotic 
muscles generally exhibit increased stiffness and reduced force output compared 
to healthy muscle. Atrophy will likely accompany fibrosis and further contribute to 
the force loss. The cause of fibrotic progression in skeletal muscle can be from 
acute traumatic injuries, chronic overuse, or inherent genetic predispositions. In 
any case, it usually results secondary to an initial insult to the muscle and a failed 
regeneration attempt. Instead of satellite cell proliferation and fusion, there is a 
prolonged immune response that increases fibroblast activation and production of 
collagen. Once fibrotic programming has begun, it is difficult to slow or reverse the 
process due to a variety of factors. 
For one, an increased area of ECM results in an increased distance from 
capillaries to myofibers, creating a hypoxic environment. A hypoxic environment 
increases expression of hypoxia-inducible factor-1α (HIF-1α) in muscle fibers. 
Coupled with increased TGF-β1 expression, HIF-1α stimulates production and 
secretion of CCN2/CTGF from muscle fibers.84 Fibroblasts become activated by 
the secreted CCN2/CTGF, resulting in more ECM deposition, which further 
increases the distance of capillaries to myofibers. Valle-Tenney et al. have termed 
this process a “vicious oxygen cycle,” and propose it as a mechanism for fibrotic 
progression in skeletal muscle.84  
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In addition, prolonged inflammatory signaling results in oxidative stress due to 
the overwhelming presence of reactive oxygen species (ROS) relative to 
antioxidants. ROS generation is currently attributed to two main endogenous 
sources; mitochondria as a by-product of cellular respiration, and NADPH oxidase 
(NOX) as a primary function.85 The NOX family includes seven isoforms, of which 
NOX2 and NOX4 are implicated in muscle regeneration due to their presence in 
phagocytes and fibroblasts, respectively.86 ROS generated from these enzymes is 
a necessary step in the repair process by activating MAPK and NF-kB pathways, 
which helps to clear necrotic tissue and induce apoptosis of unwanted cells.87 In a 
healthy regeneration model, the rise in ROS from NOX4 is combated by activation 
of Nrf2, a key regulator of antioxidant production.88 Under quiescent conditions, 
Nrf2 is generally degraded by Keap1 (Kelch ECH associated protein 1), but upon 
stress Keap1 is inactivated and thus Nrf2 can translocate to the nucleus for 
transcription.89 Nrf2 upregulates numerous antioxidant genes, including 
superoxide dismutase (SOD),90 which converts superoxide (O2-) to hydrogen 
peroxide (H2O2).85 The upregulation of SOD and other antioxidants are typically 
enough to neutralize excess ROS and restore the redox balance. Accordingly, the 
NOX4/Nrf2 ratio is emerging as a factor in the progression of multiple diseases, 
including idiopathic pulmonary fibrosis and cardiovascular disease91,92. Chronic 
ROS elevation under fibrotic conditions most likely augments the pathologic 
progression by stimulating TGF-β1 expression.93 Furthermore, TGF-β1 and HIF-
1α have been shown to increase NOX4 expression,94,95 implicating hypoxia as a 
likely contributor of ROS production, creating a cyclic feedback loop. A recent 
study by Hanley et al. used pharmacological inhibition of NOX4 to prevent cancer-
associated fibroblast accumulation and slow tumor growth in vivo.96 Although 
therapies for reversing fibrosis will likely have to be multifaceted, NOX4 may be a 
good target of inhibition. 
 
Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is genetic disorder caused by a mutation 
in the gene that encodes dystrophin, resulting in the loss of the protein throughout 
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various skeletal muscles.97 Muscle fibrosis increases dramatically over time, as 
without dystrophin the muscles continually undergo damage and a subsequent 
failed regeneration leading to ECM accumulation and weakness. The exact 
mechanism by which the loss of dystrophin contributes to muscle degradation is 
not entirely understood, but it is well-known that the muscle is more susceptible to 
injury and has a reduced capacity to recover and regenerate. Eccentric muscle 
contractions have been shown to be particularly detrimental to patients with DMD, 
making exercise a cautious treatment option.98,99 DMD affects males, and results 
in progressive loss of function leading to wheelchair assistance by early teenage 
years. Eventually the diaphragm weakens as well, causing respiratory failure; 
however, advancements in care have allowed many affected by the disease to live 
into their 30s. 
A model for studying DMD was developed using mice that have lost expression 
of dystrophin, known as mdx mice. These mice exhibit a similar phenotype to DMD 
patients, although somewhat milder, making them a good model for learning more 
about the disease and fibrotic muscle in general. Similarly, golden retriever 
muscular dystrophy (GRMD) dogs are another good model and display a more 
severe phenotype closer to that of humans.100 Muscle biopsies from DMD patients 
can also be used to understand disease progression; however, using animal 
models has the advantageous capability of testing experimental therapeutics. 
Decades of research has revealed that skeletal muscle from DMD patients and 
animal models display an ever-increasing amount of ECM accumulation with age, 
along with a combination of abnormal hypertrophied and atrophied muscle 
fibers.101,102,103 There appears to be early degradation of fast-twitch fibers (type 
IIx/b) resulting in greater proportions of slow-twitch (type I) fibers.104 However, 
these slow-twitch fibers are also at a reduced oxidative capacity compared to 
healthy controls.105 GRMD dogs were shown to have significantly increased 
CCN2/CTGF expression compared to control dogs just 30 days after birth, and 
increased collagen III expression at 60 days.103 Furthermore, Stephens et al. 
observed increased relative amounts of collagen type III in DMD patients, along 
with thickened basement membranes of collagen IV surrounding muscle fibers.102 
24 
 
Goldpsink et al. suggest that age-related increases in fibrosis are not due to an 
increase collagen gene expression, but rather a reduction in degradation due to 
increased cross-linking of collagen fibers.101 Additionally, specific ECM 
components may not proportionally increase with overall ECM accumulation, and 
can even decrease relative to age-matched controls. For example, Zanotti et al. 
found that decorin mRNA and protein levels were decreased in muscle biopsies of 
pediatric DMD patients relative to age matched controls, although significant 
fibrosis was present.106 However, multiple studies have found results contradicting 
that notion,107,108,109 possibly highlighting variability resulting from age and severity 
of phenotype.  
Because of the debilitating condition DMD patients face, treatment options 
have been heavily researched, albeit with varying degrees of success. Mdx mice 
are typically the first to receive experimental treatments; however, because they 
exhibit a milder phenotype, treatments often work better in the mice than they do 
once in larger animals or clinical trials. Nonetheless, evaluating treatments with 
mdx mice is still an invaluable step in the process of finding something that works. 
Loss of myostatin, either from genetic manipulation or pharmacological inhibition, 
has shown promising results in mdx mice.110,111 Results have included significant 
increases in muscle fiber size and maximal force output, as well as attenuation of 
fibrosis. Myostatin inhibition (by administration of ACE-031, a solubilized activin 
type IIB receptor) in a clinical trial of DMD patients saw positive results as well, 
although not as robust and accompanied by various side effects.112 The avenue of 
myostatin inhibition for DMD patients looks promising, yet it does not solve the 
underlying issue of their genetic mutation. It can help relieve symptoms of the 
disease but will not cure it. 
Potentially long-lasting therapeutic approaches for DMD include viral based 
gene therapies. Typical viral gene therapies take copies of the desired genetic 
information, as DNA or RNA, packed into a specific viral vector, such as 
adenovirus or lentivirus, which then enters the cell and releases the new genetic 
material. However, because the full-length dystrophin gene is so large (427 kD), it 
cannot fit inside a typical viral vector.113 To solve this issue, shortened versions of 
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the dystrophin gene, or mini-dystrophin, have been developed that still result in 
functional proteins.114 These can then be packaged into the viral vector of choice 
for systemic delivery of the new gene. Recent clinical trials from multiple drug 
companies using mini-dystrophin delivered via adeno-associated virus (AAV) 
capsids in boys with DMD have been encouraging enough to move on to their next 
phases. Moreover, AAV vectors have also been used to deliver CRISPR/Cas9 
components in mdx mice to delete a specific mutated exon that is known to create 
a premature stop codon in the dystrophin RNA.115 CRISPR/Cas9 technology likely 
has a promising future for DMD patients, leading to permanent dystrophin 




Another condition presenting with impaired skeletal muscle health is cerebral 
palsy (CP). CP is thought to be caused by abnormal brain development or brain 
injury sometime during the prenatal, perinatal, or postnatal period.117 The most 
common type of the disease is known as spastic CP, affecting the motor cortex 
region of the brain, which results in a reduced capacity to recruit motor units for 
voluntary movement. CP has been defined as a non-progressive condition,118 yet 
muscle pathology secondary to the underlying condition can certainly become 
progressive.119 Fibrosis is one of the hallmark signs of muscle pathology in patients 
with CP and likely contributes to the muscle stiffness observed. Patients with 
spastic CP often describe their muscles as feeling stiff when attempting to contract. 
Common complications of CP include scoliosis, hip dislocation and fixed muscle 
contractures.119 Accordingly, gait problems often present an additional detriment 
to overall function and gait and motion analysis is frequently used to support 
treatment programs.120  Exercise regimens for CP patients involving aerobic and/or 
resistance training, although safe, appear to be of little benefit in terms of gross 
motor function.121,122 
Recent findings from children with CP indicate an increase in overall muscle 
collagen content compared to typically developing children.123 Moreover, the ratio 
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of collagen I to III was decreased, suggesting an increased fraction of collagen III 
in the muscle of children with CP.  Interestingly, proteoglycan analysis revealed an 
increase in decorin content but decrease in biglycan content. Biglycan has been 
shown to be important for maintaining synapse stability in the NMJ,124 and there is 
reason to believe the NMJ is affected by CP.125 Thus, the authors suggest 
administration of biglycan as a possible therapy for CP patients.123  
 
Volumetric Muscle Loss 
Volumetric muscle loss (VML) occurs when a significant portion of muscle is 
destroyed from a traumatic event, such as a high-energy blast wound during 
combat,126 or from surgical debridement of tissue.127 Thus, this condition is 
predominant among service members due to the risks of sustaining such a 
traumatic injury. Roughly 75% of all combat related injuries in the U.S. military from 
2005 to 2009 were due to explosions, resulting in a high proportion of 
musculoskeletal injuries. Moreover, a cohort study of injured service members 
found that 92% of muscle conditions were identified as VML.127 Because of the 
chronic nature of this condition with today’s inadequate treatment options, many 
veterans of Operations Enduring Freedom, Iraqi Freedom, and New Dawn are 
dealing with lifelong functional disabilities due to VML. Although therapy is 
currently very limited regarding long term success, awareness of the issue is 
growing as evidenced by the increasing amount of research into the underlying 
physiology and treatment strategies.128,129,130,131,132,133 
At present U.S. troops are involved in active combat in 14 different countries,134 
as the global war on terror continues to be fought. The amount of service members 
affected by VML will surely continue to rise as our presence in the Middle East and 
Africa remains. It is estimated that the global burden of traumatic injuries is 
upwards of $400 billion annually, and the average cost of disability payments for 
one VML patient over a lifetime is nearly half a million dollars.127 Given that, 
discovering successful therapeutic methods to treat VML could have an enormous 
impact on the lives of currently disabled and newly injured service members both 
physically and financially. 
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In order to develop new 
therapies, it is imperative to 
first gain a better 
understanding of the 
pathophysiology responsible 
for the chronic disabilities 
observed. There have been 
great advances in this area 
recently, but still much to be 
discovered. For example, it 
is well known that following VML injury, the gap of tissue lost is too large for muscle 
fibers to bridge and thus muscle in the affected area is replaced by collagen 
deposition.135,128 This fibrotic deposition extends into the remaining muscle tissue, 
causing a loss of force output, reduced range of motion and increased 
stiffness.130,136 Figure 5 depicts the temporal change of various markers in a rat 
model of VML injury. The graph was adapted from primary data from Corona et al. 
and Aguilar et al., in addition to preliminary data on innervation from the Greising 
lab.136,137 Strength and fiber numbers are drastically reduced early on, followed by 
a partial recovery around 14 days and subsequent plateau or further decline. The 
strength loss remains roughly 50% and never fully recovers. Innervation follows a 
similar trend and continues to decline at least through 48 days after injury. 
Furthermore, recent work examining muscle architecture has shown that muscle 
fiber lengths are reduced after injury, as expected; however, the physiological 
cross-sectional area (muscle volume/fiber length) is preserved, which was an 
unexpected finding.138 The authors suggest that this preserves potential maximal 
force producing capacity. 
Changes within the ECM after VML injury have not been studied as extensively 
to this point. It has been shown that there is a dramatic increase in total collagen 
content and that gene expression of various pro-fibrotic factors (TGF-β1, CTGF, 
etc.) are increased.133 Therefore, an increase in overall collagen content following 
VML injury is expected to be observed; however, the organization of collagen in 
Figure 5. Post-VML deficits relative to controls. Modified 
from Corona et al. 2013, Aguilar et al. 2018, and 
Sorensen et al. in preparation.  
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terms of isoform proportions and how they may change over time is not 
understood. Advancing our knowledge in this aspect may be a big step in 




Current treatment options for VML include filling the lost muscle with various 
versions of decellularized collagen scaffolds and/or minced muscle grafts, with the 
hopes of guiding muscle regeneration.128,139,140,141 Although some studies using 
animal models have seen beneficial effects using these methods, no results to 
date have been clinically significant in terms of restoring muscle function. Aside 
from refining scaffold implantation, pharmacological inhibition or overexpression of 
various proteins has the potential to aid current treatment options. In particular, 
anti-fibrotic drugs may have the ability to allow scaffolds and muscle grafts to work 
better, by reducing the ECM pathology. To date, drugs that inhibit TGF-β1 activity 
have been the most studied type of anti-fibrotic, due to its well-known role in ECM 
accumulation. 
Losartan is an FDA-approved anti-hypertensive drug that indirectly blocks 
TGF-β1 by inhibiting angiotensin type II receptor I (AT1), and therefore has 
potential anti-fibrotic effects. AT1 aids in fibrotic signaling by activating the 
Smad2/3 pathway, which increases production of TGF-β1 and collagen.142 By 
inhibiting AT1, Losartan was shown to reduce fibrosis in rats after VML injury; 
however, it also led to a reduction of maximal force production.133 The force loss 
is likely due to the fact that the fibrotic deposition has capacity to transmit force,136 
and reduction of this without concurrent myogenic increases will hinder force 
output. However, there is good rational to combine this treatment with a 
subsequent myogenic treatment to overcome the limitation. 
Nintedanib is another anti-fibrotic drug that has shown effectiveness in reducing 
fibrosis after VML injury.132 Nintedanib is FDA-approved for the treatment of 
idiopathic pulmonary fibrosis (IPF).143 It is a tyrosine-kinase inhibitor, and therefore 
targets fibroblast growth factor receptor, platelet-derived growth factor receptor, 
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and vascular endothelial growth factor receptor, which are known pro-fibrotic 
factors.144 Regardless of the tissue affected, fibrotic pathologies generally have 
similar signaling pathways, and thus Nintedanib has been evaluated in the 
treatment of various diseases aside from IPF.145,146,147 Similar to findings with 
Losartan, recent results using Nintedanib in a porcine model of VML injury 
demonstrated reduction of fibrosis, which led to overall force loss.132 This further 
corroborates the notion that fibrotic tissue in skeletal muscle plays a role in force 
transmission. Yet any hope of returning muscle function to normal after VML would 
likely have to take this seemingly backwards step in order to return the ECM to a 
more permissive state for myogenesis. Conversely, Nintedanib treatment in mdx 
mice resulted in reduction of fibrosis with improved muscle function measurements 
as recorded by electromyography.148 The difference allowing mdx mice to improve 
muscle function is presumably the fact that the fibrosis is spread throughout the 
muscle with viable satellite cells able to increase myogenesis once the fibrosis is 
reduced. After VML injury, satellite cells in the defect area are removed and thus 
it becomes a challenge to replace the defect with anything other than ECM 
deposition. 
A newer emerging anti-fibrotic medication also designed for IPF, known as 
Pamrevlumab, has shown encouraging early results.149 Pamrevlumab is a 
monoclonal antibody that inhibits CCN2/CTGF activity, a factor involved in fibrosis 
as previously discussed. The drug is currently in phase 3 clinical trials for IPF and 
locally advanced unresectable pancreatic cancer, as well as phase 2 trials for DMD 
and COVID-19. Results from Phase 2 clinical trials of IPF patients suggest 
Pamrevlumab is arguably more effective at treating the condition than Nintedanib 
and had fewer adverse effects.149 Furthermore, Pamrevlumab treatment in mdx 
mice reduced fibrosis, increased muscle strength, and improved satellite cell 
grafting ability.150 Notably, these changes were achieved without any significant 
changes in TGF-β1 signaling, suggesting that CCN2/CTGF acts downstream of 
TGF-β1 and can independently modulate the fibrotic response. Pamrevlumab has 




The major gaps in the current understanding of fibrosis following VML injury 
involve the sequential cellular and molecular remodeling that results in a state 
unconducive to myogenic treatments. Protein quantification of specific collagen 
isoforms or proteoglycans following VML injury has yet to be observed. Similarly, 
protein quantification of pro-fibrotic factors, such as CCN2/CTGF, has not been 
measured over time. Furthermore, observations relating to fibrosis after VML injury 
have largely been focused on the defect area and not the remaining uninjured 
muscle. These measurements would be advantageous in deducing the optimal 
timing for future treatments, and potentially finding new targets. To address the 
important questions raised above, my thesis had the following specific aims and 
hypotheses: 
 
Specific Aim 1: Evaluate temporal changes in collagen isoform 
proportions and orientation of collagen fibers within the remaining 
muscle after VML injury. 
Hypothesis 1: Collagen III will be increased relative to collagen I at all 
time points. There will be a shift in more densely packed collagen with 
increasing time post-VML injury. 
Specific Aim 2: Evaluate CCN2/CTGF signaling in defect area and 
remaining muscle following VML injury. 
Hypothesis 2: CCN2/CTGF will be significantly increased in the defect 
area following VML injury. 
Specific Aim 3: Evaluate temporal changes in decorin levels relative 
to overall collagen content after VML injury. 
Hypothesis 3: Absolute decorin levels will increase after VML injury but 
will be reduced relative to total collagen content. 
 
These specific aims and hypotheses are addresses in Chapter 2, which include 
the final manuscript of my research project (in preparation for submission to 




Chapter 2: Research Project 




Purpose/Aim: Volumetric muscle loss (VML) is a devastating orthopaedic injury 
that results in chronic persistent functional deficits, loss of joint range of motion, 
pathologic fibrotic deposition and lifelong disability. However, to date there is only 
limited mechanistic understanding of the VML-induced fibrosis. We examined the 
temporal changes in the fibrotic deposition early after VML injury to identify a 
potential window of effective intervention. Materials and Methods: Adult male 
Lewis rats (n=48) underwent a full thickness ~20% (~85mg) VML injury to the 
tibialis anterior (TA) muscle and were harvested for genetic and histologic 
evaluation. In order to temporally track fibrotic changes, we evaluated extracellular 
proteins at 3, 7, 14, 28, and 48 days post VML-injury both biochemically and 
histologically. The contralateral TA muscle served as the control group. Results: 
The ratio of collagen I/III was decreased at 3, 7 and 14 days post-VML injury, but 
significantly increased at 48 days post injury. Decorin content followed an opposite 
trend, significantly increasing by day 14 before dropping to below control levels by 
48 days. Histological evaluation of the defect area indicates a shift from loosely 
packed collagen at early time points post-VML, to a densely packed fibrotic scar 
by 48 days. CCN2/CTGF signaling was significantly increased throughout the 
muscle at every time point. Conclusions: The shift from early wound healing 
efforts to a predominately fibrotic muscle tissue appears to occur rather 
synchronously via the significant reduction of collagen III and increase in collagen 
I after 21 days post-VML. This observation is supported by a dramatic increase in 
densely packed collagen after 21 days post-VML. Thus, there appears to be an 
early window for effective anti-fibrotic intervention, potentially by targeting 






Pathologic fibrosis is a common sequela of severe injuries and diseases 
affecting various tissues, including skeletal muscle. It is characterized by an 
excessive accumulation of extracellular matrix (ECM) components, namely 
collagen, and in skeletal muscle generally seen in conjunction with atrophy.64 The 
combination of fibrosis and atrophy limits muscle function by reducing range of 
motion and maximal force production, effectively reducing the overall quality of life 
for those affected. In minor acute injuries to skeletal muscle, such as strains and 
contusions, there is a transient period of inflammation and ECM remodeling, which 
is ultimately resolved and replaced by repaired and/or regenerated skeletal muscle 
fibers.71 However, in more severe pathologies there appears to be a tipping point 
where muscle regeneration is repressed, and ECM deposition progresses 
uninhibited.151  
A critical component of the fibrotic repair process is the timely activation and 
balance of pro-inflammatory M1, and anti-inflammatory M2 macrophages. M1 
macrophages are proposed to be responsible for clearing necrotic debris and 
activating satellite cells, while M2 macrophages control matrix remodeling and 
fusion of satellite cells.71 Notably, M1 and M2 macrophages exist at the ends of a 
continuum sequence of possible states without clear boundaries, and typically 
transition in the direction from M1 to M2.152 The imbalance or prolonged activation 
of either end of the continuum will likely result in detrimental effects to the tissue. 
For example, the initial inflammatory response is crucial for tumor necrosis factor 
(TNF) mediated apoptosis of fibro/adipogenic progenitors (FAPs), a major source 
of ECM producing fibroblasts.153 However, too early of a transition to an anti-
inflammatory state increases transforming growth factor-β1 (TGF-β1) expression, 
resulting in decreased TNF-induced FAP apoptosis and thus fibroblast 
accumulation.153 Overexpression of TGF-β1 further contributes to fibrotic 
development by stimulating fibroblasts and regenerating myofibers to produce 
collagen.154 As the area of ECM increases, so does the distance from muscle fibers 
to capillaries, resulting in a hypoxic local environment. In fact, hypoxia coupled with 
TGF-β1 expression has recently been found to stimulate myofiber secretion of 
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connective tissue growth factor (CCN2/CTGF), further increasing fibrosis and 
creating a cycle of progressive fibrotic development.84 
While research emphasis of muscle pathologies has been on the promotion 
of muscle fiber growth and regeneration without regard to fibrosis, it is becoming 
more recognized that the microenvironment in which muscle fibers reside is crucial 
to successful regeneration. The composition of ECM layers in healthy skeletal 
muscle is fairly well understood,155 yet how the ECM becomes altered from various 
fibrotic pathologies is not as clear. Therefore, a better understanding of the skeletal 
muscle microenvironment in specific pathologic conditions is necessary to 
increase the probability of improving regeneration and functional outcomes. 
Collagen types I and III are the most abundant fibrillar isoforms in skeletal muscle 
ECM, with the perimysium and epimysium layers predominately composed of type 
I.156 Type III collagen appears to be more abundant in the endomysium layer, yet 
still a component of all layers.156 Type IV collagen is the most abundant non-fibrillar 
isoform, primarily making up the basement membrane of muscle fibers, while type 
VI collagen provides a link from the basement membrane to the ECM.157 Recent 
work has indicated that type VI collagen is vital for maintaining satellite cell viability 
in skeletal muscle.158 Moreover, proteoglycans residing within the ECM, namely 
decorin and biglycan, play an important role in regulating collagen fibril formation. 
Genetic deficiencies in either decorin or biglycan have been shown to cause 
structural abnormalities in collagen fibers. 159,67  
Conditions presenting with known pathologic fibrosis of skeletal muscle 
include Duchenne muscular dystrophy (DMD), cerebral palsy (CP), and 
polymyositis (PM). Interestingly, though they differ in etiology (genetic, congenital, 
and autoimmune, respectively), all three conditions display fairly similar fibrotic 
characteristics. Biopsies from DMD, CP, and PM patients are observed to have an 
increase in the proportion of collagen III in muscle ECM.102,123,160 Recently, Smith 
et al. revealed an increase in decorin content but decrease in biglycan content in 
patients with CP.123 As the authors suggest, this is plausibly associated with 
abnormal neuromuscular junctions found in CP,125 as biglycan plays a role in 
maintaining synapse stability.124 Yet, findings in DMD patients have not been as 
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clear, with some groups reporting decreases in decorin and biglycan mRNA, 106,161  
although most have found signifcant increases in mRNA and protein content of 
both.107,108,109 
Volumetric muscle loss (VML), defined as the “traumatic or surgical loss of 
skeletal muscle with resultant functional impairment”,126 similarly generates a 
robust and lasting fibrotic response but is less understood. As VML is the result of 
an acute traumatic injury rather than a chronic underlying condition, the fibrosis 
observed after injury may display temporal differences compared to the 
aforementioned conditions. Clinically, two major problems exist in the care of VML 
injuries. First, no standard of care has been established to address the loss of 
function and mass of skeletal muscle. Second, the pathologic fibrotic response 
impedes muscle healing and regeneration, causing destruction of muscle 
architecture and altering the microenvironment of the muscle. At the tissue level, 
it is clear the lost skeletal muscle is incapable of endogenously regenerating and 
the defect area is replaced by an aberrant overproduction of ECM accumulation.128 
Yet at the molecular level, there is limited understanding of the makeup of the 
resulting fibrotic mass in terms of collagen proportions and organization, which 
could be transformative to develop and evaluate anti-fibrotic treatments for skeletal 
muscle. Previous evaluation of VML-injured muscle has indicated an overall 
increase in collagen content and upregulation of fibrotic genes such as TGF-β1, 
CCN2/CTGF, and various collagen isoforms (e.g., types I and III);133,131,130 
however, understanding of the true content and ratio of these proteins over time, 
as determined biochemically, is lacking. Herein the temporal fibrotic response after 
VML injury was evaluated in a rat model of VML injury to test the hypothesis that 
ECM components become proportionally altered after injury compared to healthy 
muscle. 
 
MATERIALS AND METHODS 
Ethics approval 
All protocols were approved by the Institutional Animal Care and Use Committee 
at the University of Minnesota; in compliance with the Animal Welfare Act, the 
36 
 
Implementing Animal Welfare Regulations and in accordance with the principles 
of the Guide for the Care and Use of Laboratory Animals. 
 
Experimental design and animal model 
Male Lewis rats (Charles River, n=39) underwent unilateral VML injury to the left 
tibialis anterior (TA) muscle and were randomized to terminal groups of 3, 7, 14, 
21, or 48 days post-VML. TA muscles were harvested from injured (left) and 
contralateral (right) hindlimbs at the given terminal time points for histological and 
biochemical analysis. Muscles from the contralateral limbs were used as controls 
for all outcome measures and collapsed into one group. Rats were given at least 
one week to acclimate to the facility prior to study. All rats were given food and 
water ad-libitum throughout the duration of the study and maintained on a 14:10 
hour dark:light cycle. At the time of surgery and randomization, rats were on 
average at 3.7 ± 0.2 months of age and 379 ± 21g of weight. At the terminal time 
point, rats were euthanized by overdose of sodium pentobarbital (>100mg/kg i.p.) 
while under isoflurane anesthesia and skeletal muscle was harvested and stored 
for further analysis.  
 
Surgical creation of volumetric muscle loss injury 
All rats in the study underwent surgery to create a full thickness VML injury to the 
left TA muscle, as previously described.162 Rats received analgesic injection (SR 
buprenorphine, 1.2mg/kg s.q.) roughly 2 hours prior to the start of surgery. Rats 
were then anesthetized with isoflurane (1.5-3.0%) throughout the duration of the 
surgery. Briefly, an anterior incision was made through the skin, and the fascia was 
cut to expose the TA muscle. A metal plate was inserted behind the TA, and a 
6mm punch biopsy was taken to remove ~20% (85 ± 13mg) of the TA muscle. 
Proline sutures were used as a reference to identify the defect area at the time of 
harvest. Following VML injury, the fascia was sutured and the skin was stapled. 
Rats were monitored twice daily for three days post-surgery, and once a week 
thereafter for signs of pain and complications. There were no incidence of adverse 
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events in the study and rats healed and recovered ambulatory ability promptly after 
surgery. 
 
Histological and image analyses 
For each terminal time point, the whole TA muscle from both left and right 
hindlimbs was harvested, blotted dry and subsequently weighed. The distal half of 
the VML defect area and approximate area on the contralateral limb was mounted 
on cork using tragacanth gum for histological evaluation. The tissue was placed in 
2-methylbutane cooled by liquid nitrogen to freeze, and subsequently stored at -
80°C until further analysis. The TA muscle was sectioned at 10µm using a Leica 
cryostat and microtome and placed on glass slides.  
Muscle fiber numbers and area of fibrosis were obtained using a Masson’s 
trichome stain (Thermo Scientific Richard-Allan Scientific Chromaview Kit; 87019) 
following manufacturer instructions. Once stained, images were obtained using a 
20X objective (0.75 NA, 0.5 µm/pixel resolution) on the brightfield Huron 
TissueScope LE slide scanner (Huron Digital Pathology, St. Jacobs, ON, Canada). 
Images were then analyzed using FIJI (ImageJ) software,163 with the “multi-point” 
function used to count fibers and the “freehand selection” function used to measure 
area of fibrosis. 
Visualization and quantification of collagen orientation was obtained using 
a picrosirius red stain under polarized light. Briefly, frozen sections were fixed in 
4% PFA for 10 minutes, rinsed in deionized water and subsequently placed in 
picrosirius red solution (0.1% Direct Red 80, 1.2% picric acid; Abcam, ab246832) 
for 60 minutes. Sections were then quickly rinsed in 3 changes of 0.5% acetic acid 
(~10 dips each), dehydrated in 2 changes each of 95% and 100% alcohol (1 minute 
each) and cleared in xylenes before being immediately mounted with DPX 
mounting medium (Electron Microscopy Sciences). The slides were then viewed 
and imaged using a Nikon Eclipse 200 light microscope with diascopic cross-
polarized filter at 40x magnification (E Plan 40x/0.65 OFN20) using digital camera 
interfaced to Nikon Elements D software. Regions of interest (ROI) for analysis 
included the VML defect area, the remaining uninjured muscle, and two images 
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along the border region of the defect and remaining muscle. For the contralateral 
control limbs, analogous regions were imaged, however a single control value is 
presented for comparison. During all imaging gain, offset, gamma, and exposure 
were constant. The area of red and green staining within ROI boxes were obtained 
using FIJI.163 Specifically, two thresholds were applied using the ‘a* channel’ in the 
CIELAB color space. A green threshold was made by setting the upper threshold 
to 128 and lower threshold to 0, while adjusting the lightness value to ~30. The 
upper threshold in the ‘b* channel’ was set to 220 in order to remove yellow pixels. 
An orange/red threshold was then made by setting the ‘a* channel’ lower threshold 
to 128 and upper threshold to 255, while adjusting the lightness value to ~45. A 
yellow threshold was added to the calculations of orange/red by setting the upper 
threshold of the ‘a* channel’ to 128, and lower threshold of the ‘b* channel’ to 220.  
The images were then binarized in their respective thresholds and measured for 
area. Data is presented in two ways, first, as the orange/red/yellow and green area 
independently and second, as a ratio of the orange/red/yellow to green area. With 
a lower ratio indicating collagen that is aligning in parallel to muscle fibers and 
greater ratios indicating disorganized collagen alignment to the longitudinal axis of 
the muscle fibers as previously described. 
The TA was also stained with anti-CCN2/CTGF. Following fixation in 4% 
PFA for 10 minutes, sections were washed with PBS and blocked in 10% goat 
serum in PBS for 1 hour. Sections were incubated in primary antibody solution (5% 
goat serum in 0.5% Tween-TBS) overnight in 4°C. Primary antibodies included 
anti-CCN2/CTGF (Abcam: ab5097, 1:200). Sections were washed with TBS and 
incubated with an Alexa-Fluor 488 conjugated secondary antibody in 5% goat 
serum in 0.5% Tween-TBS for 1 hour at room temperature. DAPI was also added 
to stain for nuclei. Sections were washed with PBS and mounted with Fluoro-Gel 
mounting medium (Electron Microscopy Sciences). Imaging and analysis of 
muscle ROI’s followed the same strategy as described for the picrosirius red. 
Briefly, image ROI’s were collected within the VML defect, the remaining tissue 
and at the border where the VML defect and the remaining tissue converge. For 
the control limbs, analogous regions were imaged and a single control value is 
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presented for comparison. Images were taken using an automated Nikon C2 
upright confocal microscope (Nikon Instruments Inc., Melville, NY) at a 
magnification of 20X (PlanApo 0.75 NA, 0.31 µm/pixel resolution). For analysis, 
images were binarized and the image intensity threshold was determined using 
the Otsu algorithm (FIJI) to measure the CCN2/CTGF area per ROI. Data are 
presented as a percentage of the total image area.  
In all cases, the expected staining patterns in normal skeletal muscle were 
observed and the specificity of anti-labeling (CCN2/CTGF) was confirmed by the 
absence of staining outside expected structures and was consistent with 
manufacturer’s technical information. For display purposes only, images were 
down-converted, without introducing any changes in brightness or contrast and 
produced in Adobe Photoshop (Adobe Systems Inc.). During all fluorescent 
imaging, the laser intensity and gain were kept consistent across samples. 
Investigators were blinded during all imaging and post-imaging analyses. 
 
Biochemical analyses 
Following harvest, the uninjured portion of TA muscle tissue distal to the VML 
defect area, and approximate area on the contralateral limb, was cut vertically into 
two pieces (medial/lateral), snap-frozen using liquid nitrogen and stored at -80oC 
until analysis. The lateral piece of each muscle was used to measure specific 
collagen isoforms, in addition to the protein content of decorin. Quantification of 
collagen I, III, IV, and VI (MyBioSource, COL1α2-MBS2023826, COL3α1-
MBS2023591, COL4α1-MBS7226846, COL6α1-MBS102349) was conducted by 
ELISA. Briefly, tissues were weighed and homogenized in a 10-mM phosphate 
buffer at a ratio of 1:100 (mg/µl), using a glass pestle tissue grinder over ice. The 
resulting homogenate was centrifuged for 5 minutes at 10,000 g, and the 
supernatant was aliquoted for immediate storage at -80°C. Total protein content 
was analyzed using the Protein A280 application (1 Abs = 1 mg/ml) on a NanoDrop 
One spectrophotometer (Thermo Scientific) after one freeze/thaw cycle. Samples 
were analyzed for specific collagen isoforms using the respective ELISA kits as 
indicated by the manufacturer and normalized to protein content. The distal-medial 
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piece of each TA muscle was then used to measure total collagen content. This 
was determined by quantifying the content of hydroxyproline in the muscle sample, 
as previously described.164  
 
Immunoblot analyses  
Fifteen µg of total protein were separated by 4-20% SDS-PAGE, transferred onto 
a PVDF membrane, and immunoblotted. Anti-decorin (Proteintech: 14667-1-AP; 
1:500) primary antibody was detected using a corresponding horseradish 
peroxidase-conjugated secondary antibody (Cell Signaling: #7074, 1:1000). 
Protein detection was obtained using Clarity Max ECL Western Blotting Substrate 
(Bio-Rad). Immunoblots were visualized with stain-free and chemiluminescent 
imaging using a ChemiDoc System (Bio-Rad Laboratories, Hercules, CA). 
Immunoblots were normalized to total protein in lane and quantified using Bio-Rad 
Laboratories Image Lab software (Hercules, CA). For decorin primary antibody, 
single bands were identified at 70 kDa as expected and consistent with 
manufacturer’s technical information. 
 
Statistical analysis 
Analysis was performed with JMP Pro statistical software (version 14.2 SAS 
Institute, Cary, NC, USA). Dependent variables for controls, day 3, 7, 14, 21, and 
48 were analyzed by one-way ANOVA across time points. When significance was 
found, Tukey’s HSD post-hoc analysis was used to ascertain specific time point 
significance. Data are presented as mean±standard deviation (SD). Statistical 
significance level was set at p≤0.05. During all evaluation the research team was 
blinded to the experimental groups. 
 
RESULTS 
Animals   
Following VML surgery, all rats recovered promptly and without complications. 
Overall body weights steadily increased with time after injury, as expected. Rats in 
the 48 day group were on average 15% heavier at the terminal time point than at 
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surgery, as expected. In parallel the weight of the control (right, uninjured) TA 
muscle increased over time post-injury. While the weight of the VML-injured TA 
muscle decreased compared to control at all times points after day 3. Specifically, 
at 48 days post-VML, the injured TA muscle was ~18% smaller than the control 
TA muscle (Table 1). 
Histologic Presentation of Fibrosis following VML Injury 
Gross histologic presentation of the TA muscle following VML injury was 
qualitatively evaluated using Masson’s Trichrome staining (Figure 6). Broadly 
there is significant fibrotic deposition that begins to develop as early as 7 days 
post-VML, as well as substantial cellular infiltration into the VML defect area. By 




Table 1. Whole body and skeletal muscle characteristics 
  Days post-VML  
 Contralateral 
control (n=9) 












































TA weight (mg) 






















1.35 ± 0.17 <0.0001 
TA protein 
content (µg/mg) 











Contralateral controls from a sub-set of animals are collapsed over time points for data from TA muscle. 
Data analyzed by one-way ANOVA; differences are indicated as *different than control; †different than day 14; 




Staining for picrosirius red was used to visualize and evaluate collagen 
packing (Figure 7A-B). Using cross-polarized filters, staining exploits the 
birefringent properties of collagen, displaying a spectrum of red to green hues and 
eliminating non-collagenous structures. Historically, hue differences were thought 
to distinguish collagen I from collagen III based on thickness, with collagen I 
(thicker) staining red/orange/yellow and collagen III (thinner) staining green.165 
However, it is unlikely hue differences are specific to collagen types, given that 
immature collagen I may be relatively thin. Rather, it is likely indicative of collagen 
packing, whereby loosely packed collagen appears green and densely packed 
collagen appears red/orange/yellow. Therefore, the area fractions of collagen 
stained red/orange/yellow and the area stained green were quantified in the TA 
muscles. Muscle sections were evaluated at three systematically selected ROIs: 
the remaining muscle, the defect area, and the border between the defect and 
remaining muscle. As expected, the total fraction of the polarized area increased 
over time in the defect and border regions post-VML. Specifically, the green area 
fraction increased significantly at 7, 14, and 21 days in both regions before 
declining at 48 days (p≤0.045), while the red/orange/yellow fraction continued to 
significantly increase through 48 days (p≤0.0001; Figure 7C-E). Thus, the ratio of 
red/orange/yellow to green in defect and border regions was decreased at early 
time points post-VML before significantly increasing after 48 days (p≤0.007; Figure 
7G-H). Remarkably, the total fraction area in the remaining muscle was also 
significantly increased after 7 days post-VML. While the red/orange/yellow area 
was significantly increased at all time points after 7 days, the green area was 
significantly increased at 21 days post-VML. The ratio of red/orange/yellow to 
green in the remaining muscle was slightly lower than controls following VML, and 
 
Figure 6. Masson’s trichrome staining was conducted across time points to evaluate the progressive fibrotic deposition 
following VML injury. Representative images from each time point are displayed, connective tissue is blue and muscle 
fibers are red. Scale 1mm. 
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significantly so at 3 and 21 days post-VML (p≤0.018; Figure 7F), indicating an 




Figure 7. A) Representative whole TA muscle stained with picrosirius red; example is from 21 days post-VML. 
Areas staining green represent loosely packed collagen, while areas staining red/orange/yellow represent more 
densely packed collagen. Scale 1mm. B) Representative images taken from the border region of defect area across 
time points and analogous control region. Scale 50µm. Total area fraction of collagen separated into 
red/orange/yellow and green fractions across post-VML time points are shown for the C) remaining muscle 
(p<0.0001), D) border region (p<0.0001), and E) defect area (p<0.0001). Ratio of orange/red/yellow fraction to 
green fraction are plotted from F) remaining muscle (p<0.009), G) border region (p<0.0001), and H) defect area 
(p<0.0001). Dashed line indicates averaged control average. Images were randomly selected from respective regions 
for analysis. One image was analyzed from remaining muscle and defect area, while two images were analyzed from 
each border region and plotted as separate points. Data analyzed by one-way ANOVA and indicates as *different 
than control; ¥ different than day 3; †different than day 14; ‡different than day 21; §different than day 48 
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Staining for CCN2/CTGF was used to observe and evaluate fibrotic 
signaling in the same ROIs (Figure 8A-B). The percentage of area positive for 
CCN2/CTGF was significantly increased (p≤0.004) as early as 3 days post-VML 
throughout the muscle and defect, and further stabilized or increased through 48 
days post-VML. In the defect region, the CCN2/CTGF positive area was 1.4-fold 
greater from 3 to 7 days post-VML. Similar increases were seen in the border 
region. Notably, throughout the remaining muscle CCN2/CTGF positive area did 
not increase further at any time point after 3 days post-VML but maintained 
significantly increased above control levels.  
 
 
Figure 8. A) Representative whole TA muscle stained for CCN2/CTGF (Green) and DAPI (Blue); example is from 
21 days post-VML. Scale 1mm. B) Representative images taken from the border region of defect area across time 
points and analogous control region. Scale 50μm. Percent area positive for CCN2/CTGF across post-VML time 
points are plotted from C) remaining muscle (p<0.0001), D) border region (p<0.0001), and E) defect area 
(p<0.0001). Dashed line indicates averaged control area. Images were randomly selected from respective regions for 
analysis. One image was analyzed from remaining muscle and defect area, while two images were analyzed from 
each border region and plotted as separate points. Data analyzed by one-way ANOVA and indicates *=different than 
control; ¥ different than day 3 
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Variations in Collagen, Isoforms, and Signaling following VML Injury  
Although there was an 
upward trend of total 
collagen, as determined 
by hydroxyproline 
content, it was not 
significantly increased 
at any time post-VML in 
the remaining muscle 
(p=0.09; Figure 9A), 
likely due to unexpected 
sample variability. 
However, there was a 
trend for the collagen 
content at 48 days post-
VML to be about 1-fold 
greater than the control. 
Protein levels of 
collagen III (normalized 
to protein content) were 
significantly increased 
at all time points 
following VML injury 
compared to control (p=0.026; Figure 9D). At 3 and 14 days post-VML, collagen III 
was increased by 2 to 3-fold, respectively, before a gradual decrease in protein 
levels by day 48. Conversely, collagen I was not significantly increased until 48 
days post-VML, where it rose ~2.5-fold compared to control (p<0.0001; Figure 9C). 
Accordingly, the collagen I:III ratio was reduced at 3, 7, 14, and 21 days post-VML, 
yet increased at 48 days. Protein levels of collagen IV and VI were both 
significantly increased at 7 and 48 days post-VML (p≤0.031; Figure 9E-F), yet 
scaled rather proportionally to the overall increases in total collagen.  
 
Figure 9. A) Total collagen content from injured TA normalized to muscle 
size (p=0.09). B) Collagen isoform temporal percent increase from control, 0% 
indicates control levels. Protein content of C) collagen I (p<0.0001), D) 
collagen III (p<0.0001), E) collagen IV (p<0.0001), and F) collagen VI 
(p=0.003), normalized to total protein content of the sample are plotted across 
time points post-VML. Data analyzed by one-way ANOVA and indicates 
*different than control; ¥ different than day 3; †different than day 14; 
‡different than day 21; §different than day 48 
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Content of decorin within the 
remaining muscle was significantly 
increased at 14 days post-VML compared 
to control (p=0.043; Figure 10A). 
However, by 48 days post-VML decorin 
content was slightly lower than control and 
significantly reduced compared to day 3 
and day 14 (p≤0.036).  
 
DISCUSSION 
Pathologic fibrosis is detrimental to 
muscle tissue by increasing stiffness and 
reducing maximal force production, in 
addition to impeding muscle regeneration 
by inhibiting satellite cell migration and 
differentiation166,167. However, the 
implications of fibrotic progression after 
VML injury on the overall goal of restoring 
muscle function are often overlooked. 
Previous animal models of VML injury 
have established a general increase in 
collagen I and III as well as pro-fibrotic factors observed via histological and 
transcriptome data.131,130 Yet, a detailed temporal response of ECM proteins and 
collagen organization post-VML injury has not been previously observed. Herein 
VML injury is shown to significantly increase the proportion of collagen I throughout 
the remaining muscle and densely packed fibrotic scar tissue in the defect region 
48 days post-VML. Interestingly, decorin, a known inhibitor of fibrosis, appears to 
have a somewhat inverse relationship with collagen I after injury, whereby it was 
significantly increased at 14 days before decreasing by 48 days post-VML to levels 
slightly lower than control muscle. However, before remodeling to this non-
permissive state, the proportion of collagen III and loosely packed collagen is 
 
Figure 10. A) Relative expression of decorin across 
time points post-VML. (P=0.004) Dashed line 
indicates control value of 1. B) Representative 
decorin western blot image for each time point. Data 
analyzed by one-way ANOVA and indicates 
*different than control; ¥ different than day 3; 
†different than day 14; ‡different than day 21; 
§different than day 48 
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significantly increased, providing a window for effective intervention. The ability to 
prevent or mitigate fibrosis through pharmacologic or regenerative medicine 
approaches may benefit from this through understanding of the variations in the 
ECM and muscle microenvironment following VML injury. 
Cross-sections of the mid-belly of the TA muscle, directly at the mid-point 
of the VML injury, were histologically stained to evaluate collagen organization and 
alignment. While the total area of both densely and loosely packed collagen 
fractions were significantly increased 21 days post-VML injury throughout the 
muscle, the average ratio between the two (dense:loose) was declined relative to 
control, suggesting a more disorganized ECM during the remodeling phase after 
injury. This increased proportion of loosely packed collagen is seemingly in 
agreement with findings by Smith et al. in a model of muscular dystrophy, in which 
collagen organization changes throughout the pathology.168 Yet in the defect and 
border regions loosely packed collagen was reduced after 48 days, and densely 
packed collagen significantly increased creating a more uniformed organization. 
Densely packed collagen possibly influences overall stiffness of the muscle 
tissue,168 which has been shown to increase over time following VML.132 Curiously, 
that trend was not observed in the remaining muscle, which maintained a 
heterogenous collagen organization through 48 days post-VML. However, an 
alternative interpretation of polarized hue differences is that the intensity of staining 
indicates collagen thickness, or degree of alignment, while hue indicates direction 
of collagen fiber alignment relative to the incident light.169 Given a cross-section of 
muscle fibers should be in alignment with the incident light, hue difference can then 
give an approximation of collagen fiber alignment relative to muscle fiber 
alignment, with red/orange hues of collagen at a larger angle to the muscle fiber 
and green hues aligned more parallel to muscle fibers.170 Taken with this 
interpretation, our findings indicate there is more collagen aligning parallel to the 
longitudinal axis of muscle fibers at the early time points post-VML, based on the 
increased ratios of green to red/orange/yellow. By aligning longitudinally, collagen 
would bear more of the stress applied to the muscle and take on a greater 
functional role in force transmission, which was observed in the remaining muscle 
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through 48 days. Conversely the increased proportion of red/orange/yellow in the 
defect and border regions would indicate collagen alignment at a larger angle 
relative to the longitudinal muscle axis, likely decreasing tensile strength of the 
muscle.  
All biochemical measurements of protein contents were taken in the 
remaining (i.e., uninjured) muscle directly distal to the defect area from 3-48 days 
following VML injury. Therefore, data herein indicate significant ECM changes are 
not confined to the site of injury and immediate surrounding area, but which are 
pervasive throughout the muscle. Recent work by Southern et al. further supports 
this notion as substantial disruptions in the mitochondrial network throughout the 
remaining muscle were observed well into the uninjured muscle.129 Moreover, as 
expected the proportion of collagen III in the remaining muscle increased during 
early time points post-VML. However, rather unexpected was the seemingly 
synchronized increase in collagen I and reduction in collagen III by 48 days post-
VML. The switch in collagen proportions could highlight an important phase in 
wound healing for intervention. The late increase in collagen I likely indicates a 
more heavily cross-linked ECM in the remaining muscle, and taken together with 
histologic findings, a more mature densely packed fibrotic scar tissue in the defect 
area. Addressing pathologic fibrosis through pharmacologic administration would 
preferably occur before fibrosis becomes denser, as heavily packed and cross-
linked collagen is harder to degrade. 
Both histologically and biochemically CCN2/CTGF was quantified to assess 
its role in fibrotic signaling after VML injury. Importantly, CCN2/CTGF is thought to 
act synergistically, yet downstream of TGF-β1 in the development of fibrosis. TGF-
β1 is a popular anti-fibrotic target due to its well-known role as a pro-fibrotic factor; 
however, it also plays an important role in the myogenic response and thus 
preserving TGF-β1 signaling may prove beneficial.171,153 To that extent, this study 
found robust increases in CCN2/CTGF at all time points through 48 days post-
VML, suggesting it could be an ideal target for inhibition of fibrosis independent of 
TGF-β1. Indeed, a monoclonal antibody that inhibits CCN2/CTGF, known as 
Pamrevlumab, was evaluated in mdx mice as an anti-fibrotic treatment.150 It was 
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observed to reduce fibrosis, increase muscle strength, and improve satellite cell 
grafting ability. Anti-fibrotic drugs used in VML animal models have similarly been 
successful in the reduction of fibrosis, but unexpectedly led to a reduction of force 
output.133,132 The loss in force from fibrotic reduction underlines the role of fibrosis 
in force transmission, or functional fibrosis as previously alluded.136  Therefore, 
treatments successful in reducing fibrosis would likely need to be coupled with a 
subsequent myogenic treatment to maintain and eventually increase force output 
and muscle function. 
Recently, we highlighted the ability of autologous minced muscle grafts to 
aid in muscle regeneration post-VML injury, yet muscle strength deficits were not 
able to fully recover.137 Transcriptome profiling revealed similar overexpression of 
inflammatory and fibrotic genes in muscle graft treated and non-treated groups, 
suggesting myogenic treatments alone do not mitigate these processes but remain 
hindered by them. Furthermore, Boldrin et al. demonstrated that satellite cells 
derived from mdx mice retain their regenerative capabilities when placed in a 
permissive microenvironment.172 This would suggest that, at least in part, the 
accumulation of ECM components in fibrotic muscle inhibits regenerative 
capabilities of endogenous satellite cells as well as injected stem cells or muscle 
grafts. Therefore, restoring the ECM to a permissive state would allow greater 
likelihood of successful satellite cell engraftment, in addition to improved 
endogenous regeneration. The observation of a significant reduction in decorin 
content from 14 to 48 days post-VML reveals a potential treatment avenue in that 
regard. Decorin is known to regulate collagen fibrillogenesis by binding to collagen 
I,67 and also has binding sites for CCN2/CTGF, TGF-β1 and myostatin.173 Thus, it 
has the ability to simultaneously inhibit fibrotic signaling while stimulating myogenic 
signaling.  
In conclusion, in a rat model of VML injury the early wound healing phase 
was highlighted by increased proportions of collagen III and loosely organized 
collagen, presumably following a normal muscle repair process of transient ECM 
remodeling. However, these observations were abruptly transformed by 48 days 
post-VML into a muscle dominated by collagen I and a heavily aligned and densely 
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packed collagenous defect area. Future work will seek to mitigate this fibrotic 
transition by the inhibition of CCN2/CTGF. Additionally, evaluating ECM changes 
at more time points between 14 and 48 days may allow for optimal timing of 
pharmacological intervention. As the initial inflammatory and remodeling phase is 
quite important in successful wound healing, timing of anti-fibrotic administration 
and any subsequent myogenic treatment will likely be critical, with a slightly 











Comparing our findings to known models of skeletal muscle fibrosis reveals 
interesting similarities and differences. The early ECM alterations in the remaining 
muscle following VML injury in many ways resemble features that are present in 
dystrophic muscle. For example, both appear to increase the relative proportion of 
collagen III, increase proteoglycan content, and shift to a matrix that is more 
loosely packed. Given that much of the literature regarding skeletal muscle fibrosis 
uses a dystrophic muscle model, these similarities were expected. Intriguingly, the 
eventual shift to a collagen I dominated matrix coupled with a decrease in decorin 
content in the remaining muscle following VML was not anticipated. Yet wound 
healing in other types of tissue, such as skin, does follow a similar progression of 
collagen III to increasing collagen I over time, especially in scar formation.174 Thus 
it almost seems as if dystrophic muscle is stuck in the early phase of wound 
healing, supported by the fact that it is continually being re-injured; whereas VML 
pathology advances past successful healing into a state of densely packed and 
heavily cross-linked matrix which equally limits function.  
 Future directions include evaluating various treatment options drawn upon 
the results of our current study. CCN2/CTGF is a target candidate for inhibition 
based on our findings of robust and persistent overexpression after VML injury. 
Moreover, the timing of such anti-fibrotic interventions may be critical, as the early 
inflammatory signaling and transient ECM deposition is needed for proper healing. 
Additionally, combining anti-fibrotic treatment with a subsequent myogenic 
treatment such as a muscle graft has the potential to augment results. Our current 
findings also highlight decorin as a promising potential therapeutic option. Previous 
studies using decorin injection after muscle laceration injuries found it reduced scar 
tissue formation and significantly increased strength relative to injured control 
muscle.175,70 Moreover, recent work in our lab indicated significant progressive 
denervation in the remaining muscle following VML injury. Exploring the role 
between increased denervation and fibrosis may be interesting. As previously 
noted, biglycan content is altered in CP, which is possibly a factor in the disrupted 
NMJ’s associated with the disease. Determining the direction of that relationship, 
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whether fibrosis drives denervation or vice versa, may be useful in optimizing 
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